Skip to main content

Table 1 Clinical characteristics of patients receiving GEM monotherapy.

From: Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer

Number of patients

35

Age (y)

Mean ± SD (Range)

61.3 ± 8.5 (46–77)

Gender

Male:Female

16: 19

Location

Head: Body/tail

7: 28

Follow-up time from commencement of GEM monotherapy (mo)

 

Median (Range)

7.7 (3.0–21.4)

Number of courses of GEM monotherapy

 

Mean ± SD (Range)

5.9 ± 4.0 (2–16)

GEM efficacy

Effective*: Non-effective

12: 23

  1. GEM, gemcitabine
  2. *Effective, partial response by imaging study or stable disease by imaging study with 50% or more decrease in tumor markers compared to pretreatment values